- Home
- POLE vs XOMA Comparison
POLE vs XOMA Comparison
Compare POLE & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLE
- XOMA
- Stock Information
- Founded
- POLE 2024
- XOMA 1981
- Country
- POLE United States
- XOMA United States
- Employees
- POLE N/A
- XOMA N/A
- Industry
- POLE
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- POLE
- XOMA Health Care
- Exchange
- POLE NYSE
- XOMA Nasdaq
- Market Cap
- POLE 299.8M
- XOMA 250.1M
- IPO Year
- POLE 2024
- XOMA N/A
- Fundamental
- Price
- POLE $10.20
- XOMA $23.26
- Analyst Decision
- POLE
- XOMA Strong Buy
- Analyst Count
- POLE 0
- XOMA 3
- Target Price
- POLE N/A
- XOMA $59.67
- AVG Volume (30 Days)
- POLE 20.6K
- XOMA 21.5K
- Earning Date
- POLE 01-01-0001
- XOMA 05-08-2025
- Dividend Yield
- POLE N/A
- XOMA N/A
- EPS Growth
- POLE N/A
- XOMA N/A
- EPS
- POLE N/A
- XOMA N/A
- Revenue
- POLE N/A
- XOMA $28,487,000.00
- Revenue This Year
- POLE N/A
- XOMA $14.22
- Revenue Next Year
- POLE N/A
- XOMA $34.01
- P/E Ratio
- POLE $57.63
- XOMA N/A
- Revenue Growth
- POLE N/A
- XOMA 498.72
- 52 Week Low
- POLE $9.94
- XOMA $18.35
- 52 Week High
- POLE $11.16
- XOMA $35.00
- Technical
- Relative Strength Index (RSI)
- POLE N/A
- XOMA 60.58
- Support Level
- POLE N/A
- XOMA $20.00
- Resistance Level
- POLE N/A
- XOMA $21.55
- Average True Range (ATR)
- POLE 0.00
- XOMA 1.16
- MACD
- POLE 0.00
- XOMA 0.36
- Stochastic Oscillator
- POLE 0.00
- XOMA 100.00
About POLE ANDRETTI ACQUISITION CORP. II
Andretti Acquisition Corp II is a blank check company.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.